Rezdiffra Q2 Sales Jump 71% to $364M as Madrigal Builds Pipeline with Arrowhead Deal
MDGL sits 80% above its 52-week low of $286.44.
Summary
Madrigal Pharmaceuticals posted Q2 2026 Rezdiffra net sales of $364.3 million, a 71% year-over-year increase, with over 49,000 patients on therapy. The net loss reached $57.9 million as the company invests in commercialization and pipeline expansion, including a new Arrowhead license for a PNPLA3-targeting siRNA.
Key Events · Earnings and Guidance · MDGL
-
Rezdiffra Sales Surge 71%
Driven by rising U.S. demand, Q2 2026 net product revenue reached $364.3 million, up from $212.8 million in Q2 2025. Over 49,000 patients are now on Rezdiffra.
-
Net Loss Widens on Investment
The net loss widened to $57.9 million for Q2 2026, compared with $42.3 million a year ago, as SG&A spending jumped 47% to $289.4 million, largely due to DTC marketing and an endocrinology field force expansion.
-
Inventory Write-Down
A $10.4 million charge was taken for work-in-process inventory that may not meet quality specifications, impacting cost of sales.
-
Pipeline Expansion Accelerates
Madrigal paid $25 million upfront for Arrowhead's ARO-PNPLA3 (now MGL-0795), a clinical-stage siRNA for a genetically defined MASH population. The first siRNA candidate from the Ribocure partnership was also nominated.
Analysis · MDGL · Life Sciences
Rezdiffra sales accelerated to $364.3 million in Q2, a 71% leap from the prior year, with more than 49,000 patients now on therapy. The company remains in the red—posting a $57.9 million quarterly loss—as it pours capital into a direct-to-consumer marketing campaign and the expansion of its endocrinology field force. A $10.4 million inventory write-down tied to quality issues represents a minor operational setback. With $838.9 million in cash and securities, the balance sheet stays robust, but the spotlight falls on the pipeline: the Arrowhead license for MGL-0795 brings in a genetically targeted siRNA asset, and the first siRNA candidate from the Ribocure partnership has been nominated. These moves position Madrigal to extend its dominance in MASH treatment well beyond Rezdiffra.
At the time of this filing, MDGL was trading at $515.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $286.44 to $615.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.